Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2/3 1Phase 2 1

Status

Completed 3Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 1Malignant Ascites 1EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast) 1

Interventions

Cyclophosphamide 1492Cisplatin 1414Paclitaxel 1317Radiotherapy 1261Carboplatin 1250Gemcitabine 1215Docetaxel 1109Bevacizumab 1030Fluorouracil 894Doxorubicin 792Dexamethasone 748Rituximab 719Capecitabine 716Oxaliplatin 700pembrolizumab 680Etoposide 678Irinotecan 634Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 558Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 427Pemetrexed 420

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Interventional × Paracentesis × Clear all
NCT06266091 2025-07-20

Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody

Wuhan YZY Biopharma Co., Ltd.

Phase 2 Completed
115 enrolled

Malignant Ascites

NCT04032600 2020-12-08

ATLANTIS

Charite University, Berlin, Germany

Phase NA Completed
61 enrolled
Gynecologic

Ovarian Neoplasms

NCT00836654 2009-02-05

Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group

Neovii Biotech

Phase 2/3 Completed
258 enrolled
BreastGastrointestinalGynecologic

EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡